Compare Pfizer Inc (PFE) vs Sunrun Inc (RUN) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Sunrun (RUN) trades at $11.44, down 3.46% today, with a bearish technical outlook despite strong recent earnings beats. The company shows solid fundamentals with a 17.88% net income margin and attractive valuation ratios (P/E 5.37, P/B 0.82). Recent developments include a major virtual power plant partnership with Tesla and Renew Home, expanding grid capacity to 425 megawatts.

While analyst consensus remains bullish with a $15.91 price target, negative cash flows and high debt-to-asset ratio (70.76%) present significant risks. The stock offers value potential if execution improves, but investors face volatility from operational challenges and market sentiment shifts.